Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
OBD
vs
F
FTSE All Share Index
OBD
Over the past 12 months, OBD has outperformed FTSE All Share Index, delivering a return of -63% compared to FTSE All Share Index's 0% growth.
Stocks Performance
OBD vs FTSE All Share Index
Performance Gap
OBD vs FTSE All Share Index
Performance By Year
OBD vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Oxford Biodynamics PLC
Glance View
Oxford Biodynamics is a biotechnology company that develops blood-based tests using its EpiSwitch platform, which looks at how DNA is folded in the cell to find disease signals. The company’s core work is to discover and validate biomarkers that can help identify cancer and other serious diseases earlier or more accurately than standard tests. It sells diagnostic tests and biomarker services to hospitals, clinical partners, pharmaceutical companies, and research groups. In practice, it makes money by licensing its technology, running testing programs, and working with drug developers who need better ways to select patients, measure disease, or track treatment response. Its business depends on turning complex genomic signals into usable medical tests and research tools. What makes Oxford Biodynamics different is that it does not focus on traditional gene sequencing alone. It uses 3D genomics, which examines the physical structure of DNA as a source of disease insight, and that gives it a distinct role in the diagnostics value chain. The company sits between basic science and clinical medicine, trying to convert a specialized lab method into practical tests that doctors and drugmakers can use.